Pharmacology
DrugBankDescription
Pidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics in various chemical pathways . Elevations of the acid in blood levels may be associated with problems of glutamine or glutathione metabolism . Pidolic acid, in general, is found in large quantities in brain tissue and other tissues in bound form, like skin . There are currently little to no medicines available that are clinically approved or marketed for employing pidolic acid as an active ingredient for any particular formal indication. Although pidolic acid is included in some over-the-counter, non-prescription dietary supplements for the proposed purpose of facilitating cognitive or memory enhancement, most available research suggest exercising caution in their recommendation as much more research is necessary .
Mechanism of Action
Pidolic acid is an endogenous amino acid derivative where the free amino group of glutamic acid or glutamine cyclizes to generate a lactam . Subsequently it is also a metabolite in the glutathione cycle that is converted to glutamate by the enzyme 5-oxoprolinase . Moreover, N-terminal glutamic acid and glutamine residues can either spontaneously cyclize to become pidolic acid, or be enzymatically transformed by glutaminyl cyclases . In particular, this is ultimately a form of N-termini that is a challenge for N-terminal sequencing using Edman chemistry, which necessitates a free primary amino group that is not present in pidolic acid . Pyroglutamate aminopeptidase can restore a free N-terminus by cleaving off the pyroglutamate residue, however . Additionally, pidolic acid and certain pidolic acid salts like calcium, magnesium, and potassium pidolic acid are sometimes used as skin or hair conditioning agents because of their humectant effects . In such humectant formulations, hydrophilic amine, hydroxyl, or even carboxyl groups possess high affinities for forming hydrogen bonds with molecules of water, allowing the hygroscopic formulations to attract and retain moisture in the air nearby through absorption, therefore drawing the water vapor into the formulation.
Pharmacodynamics
Pidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate in various chemical pathways . Elevations of the acid in blood levels may be associated with problems of glutamine or glutathione metabolism . Pidolic acid, in general, is found in large quantities in brain tissue and other tissues in bound form, like skin . Moreover, pidolic acid in high enough levels can act as an acidogen capable of inducing acidosis and a metabotoxin that can result in adverse health effects . Chronically elevated levels of pidolic acid are associated with at least five inborn errors of metabolism including 5-oxoprolinuria (where 5-oxoproline is otherwise known as pidolic acid), 5-oxoprolinase deficiency, glutathione synthetase deficiency, hawkinsinuria, and propionic acidemia . In particular, abnormally high levels of organic acids like pidolic acid in the blood, urine, brain, and/or other tissues results in general metabolic acidosis . Such acidosis generally occurs when arterial pH falls below 7.35 . In infants, the initial symptoms of acidosis consist of poor feeding, vomiting, loss of appetite, weak muscle tone (hypotonia), and lack of energy . Eventually, acidosis and the symptoms of acidosis can lead to heart, liver, and kidney abnormalities, seizures, coma, and possibly even death .
Metabolism
In living cells, various metabolic pathways involving pidolic acid exist: (a) glutamyl/glutaminyl (amino acid) n is converted to pyroglutamyl- (amino acid) n by glutaminyl cyclase, pyroglutamyl- (amino acid) n is then metabolised to pyroglutamic acid (pidolic acid) by pyroglutamyl peptidase; (b) via the gamma-Glutamyl cycle, gamma-Glutamyl transpeptidase generates gamma-Glutamyl amino acid which is metabolised to pyroglutamic acid via gamma-Glutamyl cyclotransferase; (c) glutamate via gamma-Glutamylcysteine synthetase or Glutamine synthetase or Glutamate 5-kinase metabolism generates gamma-Glutamyl phosphate which itself can be converted to pyroglutamic acid; and (d) glutamate or glutamine can be non-enzymatically converted to pyroglutamic acid . Finally, pyroglutamic acid (or pidolic acid) itself is metabolized to glutamate via the 5-Oxoprolinase enzyme .
Absorption
In skin conditioning agents, it has been observed that the percutaneous absorption of 5, 10, and 20% sodium pidolic acid through human skin was 5.97, 6.78, and 5.89%, respectively .
Toxicity
High levels of pidolic acid in the blood can lead to 5-Oxoprolinuria, which can ultimately result in severe metabolic acidosis, hemolytic anaemia, or even central nervous system dysfunction .
Indication
There is currently no clinically approved and/or marketed medicine that relies upon pidolic acid as an active ingredient for any formal therapeutic indication. Although pidolic acid may be sold in a variety of non-prescription, over-the-counter dietary supplement products for cognitive or memory enhancement, there are many studies that suggest that such products or such supplementation do not elicit any kind of cognitive benefit to users . In fact, the general suggestion for any such pidolic acid product is to exercise caution in their recommendation as much more research is necessary . Pidolic acid and sodium pidolic acid are, however, used to some extent in skin and hair conditioning agents owing to their humectant characteristics .
Half-life
Some studies have determined that the specific half-life of the N-terminal glutamic acid is about 9 months in a pH 4.1 buffer at 45 degrees Celsius .
Protein Binding
Readily available data regarding the protein binding of pidolic acid is not available.
Elimination
In the dog animal model, it was determined that 30% of an absorbed oral administration of pidolic acid was excreted unchanged in the urine and the remainder converted to urea .
Volume of Distribution
Readily available data regarding the volume of distribution of pidolic acid is not available.
Clearance
Readily available data regarding the clearance of pidolic acid is not available.
Effect Profile
CuratedStrong stimulation with moderate sensory enhancement, low euphoria
Strong anxiety/jitters and stimulation with low euphoria and focus
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Data on genuine pharmacodynamic tolerance are sparse; decreases in subjective effect with short‑interval reuse may reflect neurotoxic depletion/dysfunction rather than reversible tolerance. Conservative spacing (≥4 weeks) is recommended in harm‑reduction communities, but even isolated exposures may carry persistent risk.
Cross-Tolerances
Harm Reduction
drugs.wikiPCA is used as a research tool to selectively ablate serotonergic axon terminals; authoritative biomedical descriptors classify it as a potent serotonergic neurotoxin rather than a therapeutic or recreational agent. In rodents, PCA causes marked, long‑lasting reductions in serotonergic markers and selective degeneration of dorsal raphe projections after single exposures; behavioral sensitization to other psychostimulants can persist for weeks, indicating durable neuroadaptations. Its neurotoxicity likely involves oxidative metabolic activation to reactive intermediates in liver and brain microsomes and massive 5‑HT release producing downstream excitotoxic/oxidative stress. Because the hazard stems from the mechanism (powerful SERT‑mediated release plus toxic metabolites), combining PCA with any serotonergic drug (MAOIs, SSRIs/SNRIs, MDMA, DXM, tramadol, triptans, linezolid/methylene blue, St John’s wort) greatly amplifies risks of serotonin syndrome and hyperthermia. Even brief physical exertion or hot venues can worsen hyperthermia; cooling, rest, and conservative fluid intake (small, regular sips; avoid overhydration) are essential if unintentional exposure occurs. Community harm‑reduction alerts (2023–2025) have reported vendors listing closely related para‑chloroamphetamines (e.g., 4‑CMA) and warn of potential adulteration/substitution; verified lab drug checking is strongly advised if a stimulant of uncertain identity is encountered. If exposure occurs, avoid redosing and other serotonergics for at least several days; seek medical help urgently for agitation, muscle rigidity, high fever, confusion, or rapid heart rate suggestive of serotonin toxicity. Individuals with hepatic disease may be at increased risk given P450‑mediated bioactivation. Overall, PCA presents a realistic risk of lasting serotonergic injury in mammals; from a harm‑reduction standpoint, avoidance and rigorous drug checking are the principal risk‑mitigation strategies.
References
Drugs.wiki References
- MeSH descriptor: p‑Chloroamphetamine (potent serotonergic neurotoxin used as research tool)
- Selective lesioning of dorsal raphe serotonergic projections by PCA (rat)
- Metabolic activation of PCA to reactive intermediates (rat liver/brain microsomes)
- PCA toxicity in mice varies with sex, body weight, and dose (acute lethality)
- PCA neurotoxicity produces long‑lasting behavioral sensitization to stimulants (mouse)
- EMCDDA/EUDA amphetamine profile (acute risks include cardiovascular strain; hyperthermia)
- Serotonin syndrome overview (clinical risk with serotonergic polypharmacy)
- DXM toxicity and serotonin‑syndrome risk with serotonergics
- TripSit general guidance on antidepressant interactions and MAOI risks
- Bluelight discussion: neurotoxicity of halogenated amphetamines (community harm‑reduction context)
- Reddit RC alerts (2023–2025) warning of para‑chloroamphetamines in vendor stock/adulteration risk (community reports)
- Reddit RC alerts (2025) noting vendors selling 4‑CMA/4‑BA (community reports)